Clinical trial NCT00669656: Herbal Therapy for Treatment of Recurrent Prostate Cancer
Official title: A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: University of Southern California
Sponsor class: OTHER
First posted: 2008-04-30
Enrollment: 43
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is about Prostate Health Cocktail, a combination supplement that contains vitamin D3, vitamin E, selenium, green tea extract, saw palmetto, lycopene, and soy derivatives. This product is currently available on the market, as herb and vitamin supplements are not regulated by the FDA. Each ingredient has been studied in prostate cancer cells and/or in patients with prostate cancer. At the doses included in this supplement, no serious side effects have been reported.

The purpose of this study is to find out whether Prostate Health Cocktail can lower your PSA. Additionally, we will be looking to see whether taking this treatment causes any unexpected side effects, and whether certain blood tests can inform us about your disease status in addition to your PSA

Detailed description: Objectives of this study are:

* To assess the PSA response in prostate cancer patients who have a PSA-only disease recurrence after curative local therapy, during treatment with a combination herbal supplement.
* To qualitatively and quantitatively describe the toxicity profile of this herbal supplement.
* To assess changes in PSA doubling time for subjects treated with this supplement.
* To measure tissue GRP78, serum neuroendocrine markers, and circulating tumor cells, for correlation with treatment response and prostate cancer outcomes

Eligibility criteria: Inclusion Criteria::

* Age greater than or equal to 18
* Histologically documented adenocarcinoma of the prostate
* Initial treatment with radical prostatectomy or external beam radiation

  * Neoadjuvant/Adjuvant Androgen Deprivation therapy allowable, provided it was for a maximum of 24 months, with the last dose of medication at least 12 months previously
  * Neoadjuvant or adjuvant chemotherapy allowable, provided it was for a maximum of 6 months, with the last dose of medication at least 12 months previously
  * Adjuvant radiation after radical prostatectomy is allowed, provided at least 6 months have elapsed between completion of radiation and enrollment in study
* PSA recurrence, with a rising PSA, as defined by:

  * Post Radiation Therapy:

    * Absolute PSA \>2.0 ng/mL
    * PSA nadir \<4 ng/mL after radiation
    * Absolute rise of at least 0.5 ng/mL total
    * At least 2 increases in PSA, separated by at least 2 weeks; these can be separated by a PSA value which declines provided the second rising value is higher than the first rising value.
  * Post Prostatectomy:

    * Absolute PSA \>1.0 ng/mL
    * Absolute rise of at least 1 ng/mL total from nadir
    * At least 2 increases in PSA separated by at least 2 weeks; these can be separated by a PSA value which declines provided the second rising value is higher than the first value
* PSA Doubling Time (PSA DT) more than 3 months and less than 36 months

  * PSA DT to be calculated using the web-based calculator at http://kevin.phys.unm.edu/psa/ with the following constraints:

    * At least 3 values, but no more than 6
    * All values must be \>0.2
    * Values must be separated by at least 2 months
* No radiographically evident bony or soft tissue metastases
* Documented discussion between subject and physician about the option to pursue hormone therapy and/or salvage local therapy rather than enroll in this study
* Patients who received treatment with androgen deprivation for biochemical recurrence are eligible provided:

  * They did not document castration resistance (defined as 2 rising PSA values while testosteron \< 50
  * They have been off androgen deprivation for at least 3 months and have recovered their testosterone (\>150)
  * They have decided,in conjunction with their treating physician that they do not want to resume androgen deprivation
* ECOG Performance Status 0-2
* Life expectancy \> 12 months
* Adequate hepatic function (AST, ALT, bilirubin \<1.5 x ULN)
* Adequate renal function (eGFR by Cockcroft-Gault or comparable calculation \>50 ml/min)
* Willing to discontinue all nutritional supplements and 5-alpha reductase inhibitors (finasteride, dutasteride) for the duration of study treatment, unless the medication is being used to control symptoms of BPH and the patient has been taking the medication for more than 6 weeks
* Willing to discontinue all weight control medications for the duration of study treatment
* Signed informed consent

Exclusion Criteria:

* Atypical prostate carcinoma histology (ex: small cell, adenoid cystic)
* Evidence of bony or soft tissue metastatic disease on CT/MRI or bone scan or PET/CT
* Other invasive malignancy within prior 3 years, except for fully treated basal cell or squamous cell carcinoma of the skin.
* Full-dose anticoagulation therapy (warfarin or low molecular weight heparin) or antiplatelet therapy (clopidogrel or ticlopidine), with the exception of low-dose aspirin therapy (81 mg).
* Significant cardiac disease, included but not limited to angina, myocardial infarction, cardiomyopathy, congestive heart failure, and coronary artery disease which has required bypass surgery, angioplasty or stent placement.
* Significant uncontrolled comorbid condition which, in the opinion of the treating physician would compromise the subject's ability to comply with protocol requirements, or would pose undue risk for experiencing adverse events.

Primary outcomes:
measure: The primary endpoint of this trial will be PSA response
timeFrame: PSA measurement every 4 weeks
Secondary outcomes:
measure: Toxicity and side effects
timeFrame: Assessed every 4 weeks
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: USC/Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Tanya Dorff, MD
role: PRINCIPAL_INVESTIGATOR
References: